An active comparison rather than two headlines
STEP 8 enrolled 338 adults with overweight or obesity without diabetes. Over 68 weeks, it compared weekly injected semaglutide 2.4 mg with daily injected liraglutide 3.0 mg, alongside diet and activity counseling. The active-drug comparison was open-label; matched placebo groups were also included. [1]
A direct randomized comparison makes this more informative for the specific drug pair than juxtaposing results from unrelated trials. The treatments share an experimental setting and eligibility framework. Still, the answer applies to the regimens studied, not every dose, route or formulation that contains the same ingredient.
What changed over 68 weeks
Mean weight change was −15.8% with semaglutide and −6.4% with liraglutide, a difference of 9.4 percentage points. Gastrointestinal adverse events were common in both groups: 84.1% and 82.7%. Treatment discontinuation for any reason occurred in 13.5% and 27.6%, respectively. [1]
Discontinuation for any reason should not be relabeled as discontinuation caused by side effects. Likewise, similar percentages reporting any gastrointestinal event do not establish identical severity, timing or burden. A fair summary preserves the outcome labels instead of collapsing several different safety and participation measures into one verdict.
Two design details that matter
Because active treatment was known, expectations and experience could influence aspects of participation. Randomization remains valuable, but open-label does not mean the same thing as a fully masked comparison. A reader should be able to find that description without having to search the small print.
The study also used different rules for participants unable to tolerate the target regimens. [1] That makes the treatment protocols relevant to interpretation of persistence. It would be too simple to attribute every difference in discontinuation to the molecule alone while ignoring how the trial handled difficulty continuing.
The injection schedule is another part of the studied regimen, but this trial cannot separate the effect of schedule from the effect of the medicine. It compared complete treatment approaches. A preference for a daily or weekly routine remains an individual practical consideration.
Use a direct result for the right decision
This paper is about semaglutide and liraglutide. It should not be reused as a ranking of all weight-management medicines. For the separate tirzepatide comparison, read our SURMOUNT-5 analysis, which examines its own population and protocol.
For an individual treatment discussion, ask how the clinician weighs expected benefit, tolerability, access and the practical treatment routine. When comparing care services, ask who responds if continuing becomes difficult and what the membership actually covers. Our support checklist addresses that service question. A favorable drug result cannot tell you whether a particular clinic provides clear communication or dependable administrative support.